Inno Alessandro, Chiampan Andrea, Lanzoni Laura, Verzè Matteo, Molon Giulio, Gori Stefania
Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, Italy.
Cardiology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Sacro Cuore Don Calabria, Verona, Italy.
Front Cardiovasc Med. 2021 May 28;8:652186. doi: 10.3389/fcvm.2021.652186. eCollection 2021.
In clinical trials and meta-analysis, atherosclerotic vascular events (AVEs) during treatment with immune-checkpoint inhibitors (ICIs) have been reported with low incidence. However, preclinical data suggest that these drugs can promote atherosclerosis inflammation and progression of atherosclerosis plaques, and there is now growing and convincing evidence from retrospective studies that ICIs increase the risk of atherosclerotic vascular events including arterial thrombosis, myocardial infarction and ischemic stroke. Prospective studies are needed to increase knowledge on long-term effect of ICIs or their combinations with other cardio-toxic drugs, but in the meantime a careful assessment and optimization of cardiovascular risk factors among patients treated with ICIs is advisable.
在临床试验和荟萃分析中，已报道免疫检查点抑制剂（ICI）治疗期间动脉粥样硬化性血管事件（AVE）的发生率较低。然而，临床前数据表明，这些药物可促进动脉粥样硬化炎症和动脉粥样硬化斑块进展，目前来自回顾性研究的证据越来越多且令人信服，即ICI会增加包括动脉血栓形成、心肌梗死和缺血性中风在内的动脉粥样硬化性血管事件风险。需要进行前瞻性研究以增加对ICI或其与其他心脏毒性药物联合使用的长期影响的了解，但与此同时，对接受ICI治疗的患者进行心血管危险因素的仔细评估和优化是可取的。
